The inclusion of our website address here and elsewhere in this press release does not include or incorporate by reference the information on our website into this press release. Forward-Looking Statements Various statements in this release concerning Inoteks future expectations, plans and prospects, including without limitation, Inoteks expectations regarding the use of trabodenoson and its fixed-dose combination (FDC) program with latanoprost as treatments for POAG or OHT, Inoteks expectations regarding reporting top-line data of its Phase 2 trial for its FDC, Inoteks expectations with respect to the timing and success of its clinical studies and pre-clinical studies for trabodenoson, its FDC, orphan diseases, and the possibility of selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases, may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may” “suggest” or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Inoteks ability to successfully demonstrate the efficacy and safety of trabodenoson, its FDC program, its pre-clinical studies for orphan diseases, or selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Inoteks product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Inoteks ability to obtain, maintain and protect its intellectual property, Inoteks ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, the timing, cost or other aspects of a potential commercial launch of Inoteks product candidates and potential future sales of our current product candidates or any other potential products if any are approved for marketing, competition from others developing products for similar uses, Inoteks ability to manage operating expenses, Inoteks ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Inoteks dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled Risk Factors in Inoteks most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Inoteks subsequent filings with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. 1Raber S, Mandema JW, Li H, Nickens D. no dataA Model-Based Dose-Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/inotek-announces-top-line-results-120000039.html
Do not touch the dropper or allow it to touch your eye in order to avoid any contamination or eye infection. Some other symptoms of this infection are reddened and inflamed eyelid margins, crusty flakes at the base of the eyelashes, itchy and burning eyes. The Top Information On Choosing Critical Criteria Of Eye Bags | Suggestions For The EyeballsOphthalmoscopy is a test carried out to evaluate the health of the optic nerves, or a change in the cup-to-disk ratio. Scroll down to know about ageing eye problems, and how they are treated. Some people may experience a partial loss of peripheral vision. Glaucoma is a term that refers to a group of eye disorders that affect the optic nerve. biotic agents constrict the pupil and allow the fluid to flow out of the channels, which results in lowered pressure. It may also happen that some foreign body has lodged into the eye tissue which is causing constant irritation and redness of the eye. A fluid is secreted by the eye ball to facilitate proper lubrication to the eye. Childhood glaucoma often shows various other congenital abnormalities like tumour, inflammation, etc. More often than not, it is high blood pressure that plays the culprit. The following article will discuss some of the highly contagious eye diseases that occur due to exposure to infectious bacteria or viruses. Any condition that can cause a blockage or a reduction in the flow of aqueous humour through the trabecular mesh work can lead to the accumulation of this fluid in the anterior chamber. The retina and optic nerves are highly sensitive to an increase in intra ocular pressure.